ALL-049

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Relapsed, Resistant, or Intolerant Philadelphia Chromosome–Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) or Who Have the T315I Mutation

Lia Gore,[1] Mignon Loh,[2] Ching-Hon Pui,[3] Yousif Matloub,[4] Michael J Hanley,[4] Jichang Du,[4] Meliessa Hennessy,[4] Andrea Biondi,[5] Lewis Silverman[6]

[1]University of Colorado Cancer Center and Children's Hospital, Aurora, CO, USA; [2]University of Washington, Seattle, WA, USA; [3]St. Jude Children's Research Hospital, Memphis, TN, USA; [4]Takeda Development Center Americas, Inc., Lexington, MA, USA; [5]Clinica Pediatrica Universita Milano-Bicocca, Monza, Italy; [6]Dana-Farber/Boston's Children's Hospital, Boston, MA, USA

Introduction

Ph+ ALL

- Ph+ ALL accounts for 3%–5% of pediatric ALL[1,2]
- Current 5-year EFS and OS rates with TKIs + chemotherapy in newly diagnosed pediatric patients with Ph+ ALL are 60% and 86%, respectively.[3] However, the optimal approach for the treatment of pediatric patients with suboptimal responses, resistance, or intolerance to first- and/or second-generation TKIs has not yet been defined

Ponatinib

- Ponatinib is the only approved pan-BCR::ABL1 inhibitor and the only third-generation TKI designed to potently inhibit BCR::ABL1 with or without any single resistance mutation, including T315I[4,5]
- Marketing approval in more than 50 countries, including the United States and Europe, in adults with CML or Ph+ ALL that is resistant or intolerant to other TKIs or who have the T3151 mutation[4,5]

Study Aim

- Assess the PK, safety, and tolerability to determine the RP2D of ponatinib (tablet and AAF) and to determine the efficacy as measured by the rate of CR at the end of reinduction chemotherapy

Study Treatments

Ponatinib Dosing

	Body Weight			
Oral Ponatinib	<30 kg	30 kg to <45 kg	≥45 kg	Frequency / Days
Dose level 1	TBD	20 mg	30 mg	Daily / Days 1–35
Dose level -1 (reduced dosing)		10 mg	15 mg	Daily / Days 1–35

- Ponatinib adult tablet formulation will be used in patients able to swallow tablets
- Each patient's starting dose of ponatinib will be assigned based on body weight
- Initially selected doses are expected to achieve systemic exposures that approximately match adult exposures at 30 mg based on the results of population PK modeling and simulation
- Dose selection for the AAF will be in a separate cohort in phase 1 and informed by the results of a separate relative bioavailability study in healthy adult volunteers[6]

Chemotherapy Regimen: Modified UK ALL R3 Trial[7]

Reinduction Treatment (Weeks 1–4)	Days
Vincristine IV	1, 8, 15, 22
Dexamethasone PO/IV	1–15
PEG-asparaginase IV/IM	2, 15[a]
Daunorubicin IV	1, 2
Initial IT chemotherapy	1
CNS-1/2: IT methotrexate chemotherapy	15, 29
CNS-3: ITT chemotherapy	8, 15, 22, 29

Consolidation Treatment (Weeks 5–8)	Days
Dexamethasone PO/IV	1–5
Vincristine IV	3
Methotrexate IV	8
PEG-asparaginase IV/IM	9
Cyclophosphamide IV	15–19
Etoposide IV	15–19
CNS-1/2 IT methotrexate chemotherapy	8
CNS-3: ITT chemotherapy	8

[a]Day 15 PEG-asparaginase is removed in protocol amendment 2


Study Design

Phase 1/2 | Open label | Single arm | Multicenter: ≈70 study sites, 15 countries

Phase 1
Daily oral ponatinib + chemotherapy to confirm RP2D for 2 formulations: Tablet (N = 12) and AAF (N = 6)

Phase 2
Daily oral ponatinib at RP2D + chemotherapy N = 68 evaluable patients (including patients treated at RP2D in Phase 1)

- Phase 1 will establish the RP2D of oral ponatinib in combination with the chemotherapy backbone; for patients unable to swallow tablets or with a body weight <30 kg, an age-appropriate formulation ([AAF], minitablets) will be used
- Phase 1 has a rolling 6 design
  - The first cohort will include up to 12 patients (≥30 kg and able to swallow tablets) for the dose confirmation
  - Another cohort of 6 patients will be enrolled to assess the age-appropriate minitablet formulation at the RP2D



Inclusion and Exclusion Criteria

Key Inclusion Criteria

- Pediatric patients aged ≥1 year to ≤21 years at study entry
- Ph+ status:
  - Ph+ ALL or
  - Ph+ mixed phenotype acute leukemia or
  - Ph-like ALL with targetable kinase-activating lesions (US only)
- Relapsed or resistant/intolerant to ≥1 prior therapy with BCR::ABL1-targeted TKI (if US patient, must have received at least 1 prior second-generation BCR::ABL1-targeted TKI)
  Or:
  - *BCR::ABL1* T315I mutation
- Patient weight ≥30 kg (prior to AAF)
- Able to swallow tablets (prior to AAF)
- Performance status:
  - Aged >16 years: Karnofsky PS ≥50%
  - Aged ≤16 years: Lansky Play Scale ≥50%
- Adequate renal and hepatic function with no evidence of pancreatitis

Key Exclusion Criteria

- History or current diagnosis of CML, Burkitt leukemia/lymphoma, or mature B-cell leukemia
- Diagnosis of another concurrent primary malignancy
- Diagnosis of ALL, MPAL, or Ph-like ALL with targetable kinase-activating lesions after cytotoxic therapy for another cancer
- Clinically significant cardiovascular disease, including:
  - Any history of MI or unstable angina
  - History of heart block and/or clinically significant ventricular or atrial arrhythmias
  - Uncontrolled hypertension
- Uncontrolled hypertriglyceridemia (triglycerides ≥450 mg/dL)
- Current systemic use of:
  - Drugs known to prolong QTc interval or torsades de pointes
  - Drugs/supplements known to be strong inhibitors or inducers of CYP3A within 7 days of the first dose of study drug
- Previous ponatinib treatment
- Known allergies to any study drugs
- Known GI disease/procedures that could interfere with ponatinib absorption

Endpoints

Primary Endpoints

Phase 1	RP2D of ponatinib (tablet and AAF) + chemotherapy
Phase 2	CR rate at the end of the reinduction block with CR defined as[a]: • No circulating blasts • <5% blasts in BM • Normal maturation of cell components in BM • No extramedullary disease • ANC >1000/µL (or >1.0 x 10^9/L) • Platelets >100,000/µL (or >100 x 10^9/L)

Safety Endpoints

Phase 1 & 2	• Adverse events • Serious adverse events • Arterial occlusive events • Venous thromboembolic events • Adverse events of special interest (eg, pancreatitis)

Secondary Endpoints

Phase 1	• CR rate at the end of reinduction block • Characterization of *BCR::ABL1* domain mutations prior to and after ponatinib treatment • Ponatinib PK (C_{max}, T_{max}, AUC_{last})
Phase 2	• Proportion of patients who remain in CR or who achieve CR by the end of consolidation • Proportion of patients with MRD-negative status (<0.01%) at the end of each block • Proportion of patients who relapse or progress on study treatment • Time-to-event estimates EFS, PFS, and OS at 6 months, 1 year, 18 months, 2 years, and 3 years • Duration of CR • Proportion of patients who underwent HSCT following study treatment • Characterization of *BCR::ABL1* domain mutations prior to and following ponatinib

Exploratory Endpoints

Phase 1 & 2	• Change from baseline in laboratory values and cardiovascular outcomes (elevated cardiac troponin, NT-proBNP) • Biomarkers of disease sensitivity and resistance to ponatinib and/or biomarkers affecting ponatinib • Acceptability and palatability of the AAF of ponatinib based on results from Palatability Questionnaire administered during reinduction[a]

Additional Information

Participating sites

- Participating sites will be in the following 15 countries:
  Argentina, Australia, Brazil, China, Czech Republic, France, Italy, Mexico, The Netherlands, Poland, Portugal, Republic of Korea, Spain, UK, USA

Trial details

- See clinicaltrials.gov
- Clinical trial identifier: NCT04501614

Contact

- Takeda Study Registration Call Center; 1-866-835-2233
- Ask for the ponatinib pediatric trial representative; GlobalOncologyMedinfo@takeda.com

References

1. Arico M, et al. J Clin Oncol. 2010;28(31):4755-61.
2. Schlieben S, et al. Leukemia. 1996;10(6):957-63.
3. Slayton WB, et al. J Clin Oncol. 2018;36(22):2306-14.
4. Cortes JE, et al. Blood. 2018;132(4):393-404.
5. Zhou T, et al. Chem Biol Drug Des. 2011;77(1):1-11.
6. Study INCB 84344-103. Tablet Administered Orally in Healthy Participants. EudraCT #2018-002335-14.
7. Parker C, et al. Lancet. 2010;376(9757):2009-2017.
8. NCCN Clinical Practice Guidelines in Oncology. Pediatric Acute Lymphoblastic Leukemia. Version 2.2021 — October 22, 2020.
9. Mulla H, et al. J Oncol Pharm Pract. 2016;22(3):387-95.

Acknowledgments

We thank all the patients and their families, and the investigators and staff at all clinical sites, for their participation in the study. This study is sponsored by Takeda Development Center Americas, Inc. The authors acknowledge Corey Burgin, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, for medical writing support for the development of this presentation under the direction of the authors, which was funded by Takeda Pharmaceuticals, USA, Inc., and complied with the Good Publication Practice 3 ethical guidelines (Battisti WP, et al. Ann Intern Med. 2015;163:461–4).

Abbreviations

AAF, age-appropriate formulation; ABL, Abelson; ALL, acute lymphoblastic leukemia; ANC, absolute neutrophil count; AUC_{last}, area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration; BM, bone marrow; C_{max}, maximum observed concentration; CML, chronic myeloid leukemia; CNS, central nervous system; CNS-1/2, no/very low CNS involvement; CNS-3, definite CNS involvement; CR, complete remission; CYP3A, cytochrome P450 3A; EFS, event-free survival; EOT, end of treatment; GI, gastrointestinal; HSCT, hematopoietic stem cell transplantation; IM, intramuscular; IT, intrathecal; ITT, triple intrathecal; IV, intravenously; MI, myocardial infarction; MPAL, mixed phenotype acute leukemia; MRD, minimal residual disease; NT-proBNP, N-terminal pro-brain natriuretic peptide; OS, overall survival; PEG, polyethylene glycol; PFS, progression-free survival; Ph+, Philadelphia chromosome–positive; Ph-like, Philadelphia chromosome–like; PK, pharmacokinetics; PO, orally; PS, performance status; QTc, corrected QT; RP2D, recommended phase 2 dose; TBD, to be determined; TKI, tyrosine kinase inhibitor; T_{max}, time to reach first maximum observed concentration; UK, United Kingdom

Disclosures

The PON-1501 study is sponsored by Takeda Development Center Americas, Inc.
LG: Advisory board, unpaid (Amgen, Novartis, Roche, Kura, OnKure, Pfizer, Syndax); **ML**: Advisory board (Medisix Therapeutics); **C-HP**: Advisory board (Adaptive Biotechnologies); data monitoring committee (Novartis); **YM**: Employment (Takeda); **MJH**: Employment (Takeda); **JD**: Employment (Takeda); Employment (Takeda); **MH**: Employment (Takeda); **AB**: Advisory board (Novartis, Celgene, Incyte); **LS**: Advisory board (Takeda, Servier, Syndax, Jazz Pharmaceuticals)

Email address for questions or comments: lia.gore@cuanschutz.edu

For an e-Print, scan this QR code.

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from the authors of this poster.

10th Annual Meeting of the Society of Hematologic Oncology, September 28–October 1, 2022, Houston, TX (Hybrid)